Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy

Epilepsia

Volumn 50, Issue 3, 2009, Pages 422-433

  Van Vliet, Erwin A ^a,b   Aronica, Eleonora ^c   Redeker, Sandra ^c   Boer, Karin ^c   Gorter, Jan A ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Keppra; Pharmacoresistance; Status epilepticus; Temporal lobe epilepsy; Tolerance

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; MEMBRANE PROTEIN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT THERAPY; ARTICLE; AUTOPSY; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; ELECTROENCEPHALOGRAM; EPILEPSY; EPILEPTOGENESIS; FEMALE; HIPPOCAMPAL SCLEROSIS; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MOSSY FIBER; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEIZURE; TEMPORAL LOBE EPILEPSY; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANIMALS; ANTICONVULSANTS; BLOTTING, WESTERN; CHILD; DISEASE MODELS, ANIMAL; EPILEPSY, TEMPORAL LOBE; FEMALE; HIPPOCAMPUS; HUMANS; INFANT; MALE; MEMBRANE GLYCOPROTEINS; MICROSCOPY, CONFOCAL; MIDDLE AGED; NERVE TISSUE PROTEINS; PIRACETAM; RATS; SCLEROSIS; STATUS EPILEPTICUS; YOUNG ADULT;

EID: 61849097125     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2008.01727.x     Document Type: Article

References (37)

1. Bajjalieh SM, Peterson K, Linial M, Scheller RH 1993) Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci USA 90 : 2150 2154.
2. Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH 1994) Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci 14 : 5223 5235.
3. Ben-Menachem E 2003) Preliminary efficacy of levetiracetam in monotherapy. Epileptic Disord 5 (Suppl 1 S51 S55.
4. Ben-Menachem E, Edrich P, Van Vleymen B, Sander JW, Schmidt B 2003) Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 53 : 57 64.
5. Bennett B, Matagne A, Michel P, Leonard M, Cornet M, Meeus MA, Toublanc N 2007) Seletracetam (UCB 44212). Neurotherapeutics 4 : 117 122.
6. Buckley K, Kelly RB 1985) Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J Cell Biol 100 : 1284 1294.
7. Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM 1999) Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci USA 96 : 15268 15273.
8. Custer KL, Austin NS, Sullivan JM, Bajjalieh SM 2006) Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 26 : 1303 1313.
9. Danscher G 1981) Histochemical demonstration of heavy metals. A revised version of the sulphide silver method suitable for both light and electronmicroscopy. Histochemistry 71 : 1 16.
10. French J, di Nicola S, Arrigo C 2005) Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy. Epilepsia 46 : 1304 1307.
11. Friedman D, French JA 2006) Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures. Neurology 66 : 590 591.
12. Gillard M, Fuks B, Michel P, Vertongen P, Massingham R, Chatelain P 2003) Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur J Pharmacol 478 : 1 9.
13. Gillard M, Chatelain P, Fuks B 2006) Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 536 : 102 108.
14. Glien M, Brandt C, Potschka H, Loscher W 2002) Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 43 : 350 357.
15. Gorter JA, van Vliet EA, Aronica E, Lopes da Silva FH 2001) Progression of spontaneous seizures after status epilepticus is associated with mossy fibre sprouting and extensive bilateral loss of hilar parvalbumin and somatostatin-immunoreactive neurons. Eur J Neurosci 13 : 657 669.
16. Gorter JA, Borgdorff AJ, van Vliet EA, Lopes da Silva FH, Wadman WJ 2002a) Differential and long-lasting alterations of high-voltage activated calcium currents in CA1 and dentate granule neurons after status epilepticus. Eur J Neurosci 16 : 701 712.
17. Gorter JA, van Vliet EA, Aronica E, Lopes da Silva FH 2002b) Long-lasting increased excitability differs in dentate gyrus vs. CA1 in freely moving chronic epileptic rats after electrically induced status epilepticus. Hippocampus 12 : 311 324.
18. Gorter JA, Van Vliet EA, Proper EA, De Graan PN, Ghijsen WE, Lopes Da Silva FH, Aronica E 2002c) Glutamate transporters alterations in the reorganizing dentate gyrus are associated with progressive seizure activity in chronic epileptic rats. J Comp Neurol 442 : 365 377.
19. Gorter JA, Goncalves Pereira PM, van Vliet EA, Aronica E, Lopes da Silva FH, Lucassen PJ 2003) Neuronal cell death in a rat model for mesial temporal lobe epilepsy is induced by the initial status epilepticus and not by later repeated spontaneous seizures. Epilepsia 44 : 647 658.
20. Gorter JA, Van Vliet EA, Aronica E, Breit T, Rauwerda H, Lopes da Silva FH, Wadman WJ 2006) Potential new anti-epileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J Neurosci 26 : 11083 11110.
21. Janz R, Sudhof TC 1999) SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 94 : 1279 1290.
22. 2+ regulators in neurotransmitter release. Neuron 24 : 1003 1016.
23. Ketelaars SO, Gorter JA, Aronica E, Wadman WJ 2004) Calcium extrusion protein expression in the hippocampal formation of chronic epileptic rats after kainate-induced status epilepticus. Epilepsia 45 : 1189 1201.
24. Klitgaard H 2001) Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia 42 (Suppl 4 13 18.
25. Loscher W, Honack D 2000) Development of tolerance during chronic treatment of kindled rats with the novel antiepileptic drug levetiracetam. Epilepsia 41 : 1499 1506.
26. Loscher W, Schmidt D 2006) Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 47 : 1253 1284.
27. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B 2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101 : 9861 9866.
28. Meencke HJ, Meinke-Jäggi D 2004) Ursachen für sekundären Wirkungsverlust sorgsam differenzieren. PharmaFokus ZNS 1 : 3.
29. Noyer M, Gillard M, Matagne A, Henichart JP, Wulfert E 1995) The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286 : 137 146.
30. Paxinos G, Watson C 1998) The rat brain in stereotaxic coordinates. Academic Press, San Diego.
31. Sloviter RS 1982) A simplified Timm stain procedure compatible with formaldehyde fixation and routine paraffin embedding of rat brain. Brain Res Bull 8 : 771 774.
32. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC 1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150 : 76 85.
33. Sutula T 2002) Seizure-induced axonal sprouting: assessing connections between injury, local circuits, and epileptogenesis. Epilepsy Curr 2 : 86 91.
34. van Vliet EA, Aronica E, Tolner EA, Lopes da Silva FH, Gorter JA 2004) Progression of temporal lobe epilepsy in the rat is associated with immunocytochemical changes in inhibitory interneurons in specific regions of the hippocampal formation. Exp Neurol 187 : 367 379.
35. van Vliet EA, Van Schaik R, Edelbroek PM, Lopes da Silva FH, Wadman WJ, Gorter JA 2008) Development of tolerance to levetiracetam in rats with chronic epilepsy. Epilepsia 49:1151-1159.
36. von Rosenstiel P 2007) Brivaracetam (UCB 34714). Neurotherapeutics 4 : 84 87.
37. Xu T, Bajjalieh SM 2001) SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol 3 : 691 698.